Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Abstrait

Timing Treatment in Postmenopausal Women with Breast Cancer in Addition to Tamoxifen: Importance of the Tumour?s Endocrine Responsiveness

Craig Ventra, Vladimir Vernedsky

Background: Whether chemotherapy is beneficial to all breast cancer patients is still up for debate.
Clients and techniques: Tamoxifen for 5 years or Tamoxifen plus three concurrent courses of cyclophosphamide, methotrexate, and 5-fluorouracil (‘classic’ CMF) chemotherapy, either early, delayed, or both were the two treatment options given to 1212 postmenopausal patients with node-positive disease in the International Breast Cancer Study Group (IBCSG) trial VII. Tamoxifen alone or three cycles of adjuvant traditional CMF administered before tamoxifen were the two treatment options offered to 1669 postmenopausal individuals with node-negative illness in IBCSG trial IX. According to the main tumor’s oestrogen receptor (ER) content, results were evaluated.
Results: In comparison to tamoxifen alone, adding CMF early, delayed, or both decreased the probability of relapse in patients with node-positive, ER-positive illness by 21% (P = 0.06), 26% (P = 0.02), and 25% (P = 0.02), respectively. When CMF was administered to patients with node-negative, ER-positive tumours before tamoxifen, there was no difference in their disease-free survival.
Conclusions: For patients with node-positive, endocrine-responsive breast cancer, CMF given concurrently(early, delayed, or both) with tamoxifen was more efficacious than tamoxifen alone, supporting late delivery of chemotherapy even after starting tamoxifen. For individuals with node-negative, endocrine-responsive illness, however, consecutive CMF and tamoxifen proved unsuccessful.

Avertissement: Ce résumé a été traduit à l'aide d'outils d'intelligence artificielle et n'a pas encore été examiné ni vérifié.